Cellectar Biosciences CLRB
NASDAQ CLRB
$1.82 -0.01 (-0.55%)
At close: Sep 29, 2026 · 4:00 PM EDT

Cellectar Biosciences (CLRB) Debt Ratio (2010 - 2020)

Updated

Cellectar Biosciences' (CLRB) Debt Ratio came in at 0.01 for Q3 2020, up 15.2% from the prior quarter.

Analysis

Cellectar Biosciences (CLRB) Debt Ratio (2010 - 2020) Analysis & Trends

Since Q4 2010, Cellectar Biosciences has reported Debt Ratio for 26 quarters.

  • In prior years, Cellectar Biosciences' Debt Ratio was 0.04 in FY2015 (+29.6%), 0.03 in FY2014 (-49.2%), 0.07 in FY2013 (+68.4%) and 0.04 in FY2012 (-8.0%).
  • The Q3 2020 figure stands as the highest quarterly Debt Ratio since Q3 2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 0.24
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 0.52
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 0.42
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 0.31
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 0.00
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 0.60
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Cellectar Biosciences 22.38 Mn 22.38 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 0.01
Jun 30, 2020 0.01
Dec 31, 2016 0.01
Sep 30, 2016 0.02
Jun 30, 2016 0.02
Mar 31, 2016 0.05
Dec 31, 2015 0.04
Sep 30, 2015 0.06
Jun 30, 2015 0.05
Mar 31, 2015 0.04
Dec 31, 2014 0.03
Sep 30, 2014 0.03
Jun 30, 2014 0.08
Mar 31, 2014 0.06
Dec 31, 2013 0.07
Sep 30, 2013 0.05
Jun 30, 2013 0.04
Mar 31, 2013 0.03
Dec 31, 2012 0.04
Sep 30, 2012 0.04
API Access

Cellectar Biosciences Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=CLRB&period=max&api_key=YOUR_API_KEY